Expression pattern and functional studies of matrix degrading proteases and their inhibitors in the mouse corpus luteum.
The formation of the corpus luteum (CL) is accompanied with angiogenesis and tissue remodeling and its regression involves tissue degradation. Matrix degrading proteases such as plasminogen activators (PAs) and matrix metalloproteinases (MMPs) are thought to play important roles in such controlled proteolytic processes. In this study, in situ hybridization has been used to examine the regulation and expression pattern of mRNAs coding for proteases and protease inhibitors belonging to the PA- and MMP-systems during the life cycle of the CL in an adult pseudopregnant mouse model. Of the nine proteases and five protease inhibitors that were studied, the majority were found to be temporally expressed during the formation and/or the regression of the CL. However, the mRNAs coding for urokinase type PA (uPA), membrane-type 1 MMP (MT1-MMP), and tissue inhibitor of metalloproteinases type-3 (TIMP-3) were constantly expressed in the mouse CL throughout its whole life span. To study the functional role of uPA in the CL, we analyzed luteal formation and function in uPA deficient mice. Our results revealed no significant difference in ovarian weight, serum progesterone levels, and blood vessel density in the functional CL between uPA deficient and wild type control mice. The temporal and spatial expression pattern of proteases and protease inhibitors during the CL life span suggests that members of the PA- and MMP-systems may play important roles in the angiogenesis and tissue remodeling processes during CL formation, as well as in the tissue degradation during luteal regression. However, the absence of reproductive phenotypes in mice lacking uPA and several other matrix degrading proteases indicates that there are redundancies among different matrix degrading proteases or that tissue remodeling in the ovary may involve other additional unique elements.
Liu
Kui
K
Serono Reproductive Biology Institute, One Technology Place, Rockland, MA 02370, USA.
Wahlberg
Patrik
P
Hägglund
Anna Carin
AC
Ny
Tor
T
D000818:Animals; D003338:Corpus Luteum / Q000201:enzymology* / Q000254:growth & development / Q000378:metabolism; D010450:Endopeptidases / Q000378:metabolism* / Q000502:physiology; D005109:Extracellular Matrix / Q000201:enzymology*; D005260:Female; D020869:Gene Expression Profiling; D007774:Lactation; D008297:Male; D051379:Mice; D018345:Mice, Knockout / Q000235:genetics; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011480:Protease Inhibitors / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D010959:Tissue Plasminogen Activator / Q000235:genetics / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000235:genetics / Q000378:metabolism
D011480:Protease Inhibitors; D012333:RNA, Messenger; D011374:Progesterone; D010450:Endopeptidases; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator